CKD-378 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses CKD-378 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses CKD-378 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Clinical Trial to Evaluate the Food Effect of CKD-378CompletedPhase 1Chong Kun Dang PharmaceuticalNCT06386328Written as CKD-378, QD, PO
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378CompletedPhase 1Chong Kun Dang PharmaceuticalNCT05741437Written as CKD-378, QD, PO Drug: D745, D150, QD, PO
- Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy AdultsCompletedPhase 1Chong Kun Dang PharmaceuticalNCT05881213Written as CKD-378 (low-dose)